共 15 条
[1]
Antidiabetic PPAR gammaactivator rosiglitazone reduces MMF9 serum levels in type 2 diabetic patients with coronary artery disease. Marx N,Froehlich J,Siam L,et al. Arteriescler Thromb Vasc Biol . 2003
[2]
Serum matrix metalloproteinase-9 concerntration in angiographically assessed coronary artery disease. Kalela A,Loivu TA,Sisto T,et al. Scandinavian Journal of Clinical and Laboratory Investigation . 2002
[4]
The receptor RAGE as a progression factor amplifying arachidonate-depandent inflammatory and proteolytic response in human atheresclerotic plaques:role of glycemic control. Cipollone F,Iezzi A,Fazia M,et al. Circulation . 2003
[5]
Plasma concerntrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Blankenberg S,Rupprecht HJ,Poirier O,et al. Circulation . 2003
[6]
Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus in porcine coronary arteries in vivo. Morishige K,Shimokawa H,Matsumoto Y,et al. Cardiovascular Research . 2003
[9]
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Haffner SM,Greenberg AS,Weston WM,et al. Circulation . 2002
[10]
Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities,in the expression of tissue factor and matrix metalloproteinase in mononuclear cell,and in plasma tissue factor and matrix metalloproteinese. Aljada X,Ghanim H,Mohanty P,et al. The American Journal of Clinical Nutrition . 2004